Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elraglusib - Actuate Therapeutics

Next Previous
Drug Profile

Elraglusib - Actuate Therapeutics

Alternative Names: 9 ING 41

Latest Information Update: 12 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Northwestern University; University of Illinois at Chicago
  • Developer Actuate Therapeutics; Incyte Corporation
  • Class Antineoplastics; Benzofurans; Dioxolanes; Indoles; Pyrroles; Small molecules
  • Mechanism of Action Glycogen synthase kinase 3 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Pancreatic cancer; Soft tissue sarcoma; Neuroblastoma; Adenocarcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adenoid cystic carcinoma; Myelofibrosis; Neuroblastoma; Pancreatic cancer; Salivary gland cancer
  • Phase I/II Cancer
  • No development reported Brain cancer; Chronic lymphocytic leukaemia; Colorectal cancer

Most Recent Events

  • 09 Jun 2026 Phase-I/II clinical trials in Neuroblastoma (In infants, In children, In adolescents, In adults, Combination therapy, Second-line therapy or greater) in United Kingdom (IV) (CTIS2024-516115-24-00)
  • 28 May 2026 No recent reports of development identified for preclinical development in Brain-cancer in USA
  • 11 May 2026 US FDA approves IND application of elraglusib in a phase I/II trial Solid tumours (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top